Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05768958
Other study ID # H-22019913
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date March 22, 2023
Est. completion date July 31, 2026

Study information

Verified date March 2024
Source Steno Diabetes Center Copenhagen
Contact Kristine Færch, PhD
Phone +45 30913061
Email kristine.faerch@regionh.dk
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The overall aim is to investigate effects of acute exercise on ad libitum energy intake and study whether this differs between morning and evening in individuals with overweight/obesity with or without type 2 diabetes (T2D). Furthermore, the aim is to examine the role of hedonic and homeostatic drivers of appetite control in obesity and T2D in the context of meal and exercise timing.


Description:

Fifty-eight adults (age 18 - 75 years old) with overweight/obesity (BMI >25 kg/m2) and with/without T2D will participate in this randomized cross-over study. Participants will complete two visits in the morning and two in the evening with a minimum of 3 days washout. The visits will include ratings of subjective appetite and blood samples in the fasted state followed by either a 45 min exercise bout or rest for the same duration. 15 min after the termination of the exercise bout/rest period the participants will be presented with an ad libitum meal for assessment of energy intake (primary outcome). Then the participants will complete the Steno Biometric Food Preference Task (SBFPT); A computerized task measuring food choice, explicit liking, and implicit and explicit wanting with concomitant biometric measurements. Throughout the visits, subjective appetite will be rated using visual analogue scales and blood will be collected for assessment of appetite-related hormones and metabolites. (Time: -60 minutes (fasting), -45 minutes (start exercise/rest), 0 minutes (finish exercise/rest), 15 minutes (ad libitum meal), 30 minutes (finish al libitum meal), 60 minutes (end of visit) Descriptive data will be collected at a visit prior to the test days. These data include body weight (kg), Body Mass Index (BMI, kg/m2), fat mass (kg), fat free mass (kg), fat percentage (%), HbA1c (mmol/mol and %), waist circumference (cm), VO2-0peak and ECG. The participants will furthermore fill in questionnaires regarding the following: Socio-Economic Status (SES), Control Over Eating (CoEQ), Munich Chronotype Questionnaire (MCTQ), Physical Activity Questionnaires (IPAQ), Pittsburgh Sleep Quality Index (PSQI). In addition to the outcomes listed below, markers of liver function (Alanine aminotransferase (ALAT), Aspartate Transaminase (ASAT)), HbA1c, sodium, and potassium will be measured in the fasting state on the first morning visit. The specific objectives are to: 1. Assess whether energy intake during an ad libitum meal differs after an acute bout of exercise compared to a rest condition 2. Assess whether energy intake during an ad libitum meal after an acute bout of exercise differs between morning and evening 3. Assess whether appetite ratings, food reward, and metabolic markers i.e., hormones and metabolites in response to an acute exercise bout and subsequent ad libitum meal differ between morning and evening 4. Examine if the above findings differ between individuals with and without T2D 5. Identify circulating biomarkers that can be used to stratify individuals with overweight/obesity into primary hedonic or homeostatic driven in terms of ad libitum food intake


Recruitment information / eligibility

Status Recruiting
Enrollment 58
Est. completion date July 31, 2026
Est. primary completion date September 1, 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: - Adults with overweight or obesity (BMI >25 kg/m2) with and without T2D - HbA1c =48 mmol/mol for people with T2D Exclusion Criteria: - Not able to eat ad libitum meal - Not able to perform the exercise bout - Daily smoking - For women: Pregnancy / planned pregnancy (within the study period) / lactating - Self-reported history of an eating disorder in the past 3 years - Self-reported weight change (>5 kg) within three months prior to inclusion - Treatment with antidepressants - Treatment with fast acting insulin, combination insulin products and sulfonylureas - Alcohol/drug abuse or in treatment with disulfiram (antabus) at time of inclusion - Uncontrolled medical issues including but not limited to cardiovascular pulmonary, rheumatologic, hematologic, oncologic, infectious, gastrointestinal, or psychiatric disease; diabetes or other endocrine disease; immunosuppression - Current treatment with medication which significantly affect appetite or energy balance (e.g., GLP-1 receptor agonists) - Bariatric surgery - Unable to understand the informed consent and the study procedures - Concomitant participation in intervention studies - Incapable of understanding Danish

Study Design


Intervention

Other:
Exercise
45 min exercise bout performed on bicycle ergometer. The exercise bout will consist of a 10 min warm-up period at 40 % Watt max followed by 4 cycles of 4 min at 85 % Watt max and 3 min at 50 % Watt max. A cool-down period (7 min) will be performed at 40 % Watt max.
Control
45 min rest during the same time period as the exercise bout on exercise study visits.

Locations

Country Name City State
Denmark Steno Diabetes Center Copenhagen Herlev

Sponsors (3)

Lead Sponsor Collaborator
Steno Diabetes Center Copenhagen Novo Nordisk A/S, University of Leeds

Country where clinical trial is conducted

Denmark, 

Outcome

Type Measure Description Time frame Safety issue
Primary Ad libitum energy intake (KJ) after exercise compared with rest Food intake (KJ) is measured after meal completion, exercise compared with rest Measured after meal consumption at t = 30 minutes
Secondary Ad libitum energy intake (KJ) after exercise in the morning compared with evening Assess whether energy intake during an ad libitum meal after exercise differs between morning and evening Measured after meal consumption at t = 30 minutes
Secondary Ad libitum energy intake (KJ) after rest in the morning compared with evening Assess whether energy intake during an ad libitum meal after rest differs between morning and evening Measured after meal consumption at t = 30 minutes
Secondary Eating pace (KJ/min) Energy intake relative to duration of meal consumption Measured from start to finish of meal consumption at t = 15 minutes to end of meal, morning and evening, exercise and rest
Secondary Glucose (mmol/L) Concentrations of glucose Fasting (t = -60 minutes) and at t = 0, 15, 30, 45, 60 minutes, morning and evening, exercise and rest
Secondary Triglyceride (mmol/L) Concentrations of triglyceride Fasting (t = -60 minutes) and at t = 0, 15, 30, 45, 60 minutes, morning and evening, exercise and rest
Secondary Total cholesterol (mmol/L) Concentrations of total cholesterol Fasting (t = -60 minutes) and at t = 0, 15, 30, 45, 60 minutes, morning and evening, exercise and rest
Secondary LDL cholesterol (mmol/L) Concentrations of LDL cholesterol Fasting (t = -60 minutes) and at t = 0, 15, 30, 45, 60 minutes, morning and evening, exercise and rest
Secondary HDL cholesterol (mmol/L) Concentrations of HDL cholesterol Fasting (t = -60 minutes) and at t = 0, 15, 30, 45, 60 minutes, morning and evening, exercise and rest
Secondary VLDL cholesterol (mmol/L) Concentrations of VLDL cholesterol Fasting (t = -60 minutes) and at t = 0, 15, 30, 45, 60 minutes, morning and evening, exercise and rest
Secondary Free-Fatty Acids (mmol/L) Concentrations of Free-Fatty Acids. Fasting (t = -60 minutes) and at t = 0, 15, 30, 45, 60 minutes, morning and evening, exercise and rest
Secondary Circulating metabolides (metabolomics) (g/mL) Concentrations of circulating metabolides measured with metabolomic analysis Fasting (t = -60 minutes) and at t = 0, 15, 30, 45, 60 minutes, morning and evening, exercise and rest
Secondary Circulating lipids (lipidomics) (g/mL) Concentrations of circulating lipids measured with lipidomic analysis Fasting (t = -60 minutes) and at t = 0, 15, 30, 45, 60 minutes, morning and evening, exercise and rest
Secondary Circulating proteins (proteomics) (g/mL) Concentrations of circulating proteins measured with proteomic analysis Fasting (t = -60 minutes) and at t = 0, 15, 30, 45, 60 minutes, morning and evening, exercise and rest
Secondary Insulin (pmol/L) Concentrations of insulin Fasting (t = -60 minutes) and at t = 0, 15, 30, 45, 60 minutes, morning and evening, exercise and rest
Secondary Glucagon (pmol/L) Concentrations of glucagon Fasting (t = -60 minutes) and at t = 0, 15, 30, 45, 60 minutes, morning and evening, exercise and rest
Secondary Total ghrelin (pmol/L) Concentrations of total ghrelin Fasting (t = -60 minutes) and at t = 0, 15, 30, 45, 60 minutes, morning and evening, exercise and rest
Secondary Acylated ghrelin (pmol/L) Concentrations of acylated ghrelin Fasting (t = -60 minutes) and at t = 0, 15, 30, 45, 60 minutes, morning and evening, exercise and rest
Secondary Glucagon-Like Peptide-1 (GLP-1) (pmol/L) Concentrations of Glucagon-Like Peptide-1 (GLP-1) Fasting (t = -60 minutes) and at t = 0, 15, 30, 45, 60 minutes, morning and evening, exercise and rest
Secondary Glucose-Dependent Insulinotropic polypeptide (GIP) (pmol/L) Concentrations of Glucose-Dependent Insulinotropic polypeptide (GIP) Fasting (t = -60 minutes) and at t = 0, 15, 30, 45, 60 minutes, morning and evening, exercise and rest
Secondary C-peptide (pmol/L) Concentrations of C-peptide Fasting (t = -60 minutes) and at t = 0, 15, 30, 45, 60 minutes, morning and evening, exercise and rest
Secondary Peptide YY (PYY) (pmol/L) Concentrations of Peptide YY (PYY) Fasting (t = -60 minutes) and at t = 0, 15, 30, 45, 60 minutes, morning and evening, exercise and rest
Secondary Peptide YY (PYY) 3-36 (pmol/L) Concentrations of Peptide YY (PYY) 3-36 Fasting (t = -60 minutes) and at t = 0, 15, 30, 45, 60 minutes, morning and evening, exercise and rest
Secondary Fibroblast Growth Factor 21 (FGF-21) (pmol/L) Concentrations of Fibroblast Growth Factor 21 (FGF-21) Fasting (t = -60 minutes) and at t = 0, 15, 30, 45, 60 minutes, morning and evening, exercise and rest
Secondary Leptin (pmol/L) Concentrations of Leptin Fasting (t = -60 minutes), and at t = 0, 15, 30, 45, 60 minutes, morning and evening, exercise and rest
Secondary Growth Differentiation Factor 15 (GDF-15) (pmol/L) Concentrations of Growth Differentiation Factor 15 (GDF-15) Fasting (t = -60 minutes) and at t = 0, 15, 30, 45, 60 minutes, morning and evening, exercise and rest
Secondary Cholecystokinin (CCK) (pmol/L) Concentrations of Cholecystokinin (CCK) Fasting (t = -60 minutes) and at t = 0, 15, 30, 45, 60 minutes, morning and evening, exercise and rest
Secondary Pancreatic polypeptide (PP) (pmol/L) Concentrations of Pancreatic polypeptide (PP) Fasting (t = -60 minutes), and at t = 0, 15, 30, 45, 60 minutes, morning and evening, exercise and rest
Secondary C-reactive protein (CRP) (pmol(L) Concentrations of C-reactive protein (CRP) Fasting (t = -60 minutes), and at t = 0, 15, 30, 45, 60 minutes, morning and evening, exercise and rest
Secondary Food choice Food choice of food items from four combined food categories (high-fat savoury, high-fat sweet, low-fat savoury and low-fat sweet foods) examined from the SBFPT. Food choice is determined based on frequency of selection made within each food category. The scores range from 0-48 i.e. 0 = foods within a specific food category have not been selected at all to 48 = foods within a specific food category have been selected 48 times. Measured before exercise/rest (t = -60 minutes) and after meal consumption (t= 30 minutes), morning and evening, exercise and rest
Secondary Attention Measured using eye tracking in response to looking at food pictures during the computerized Leeds Food Preference Questionnaire.
Includes the following parameters: Gaze: Time spent (ms and %) and revisits (n); and fixations: Time to first fixation (ms), time spent (ms and %), fixation count (n), first fixation duration (ms), average fixation duration (ms). Distance to screen (mm), and gaze direction bias (ratio) which is calculated as the number of trials in which the first fixation was directed to a food image as a proportion to all trials. A bias score ?0.5 indicates attention towards one food image, a bias score equal to 0.5 indicates no bias, and a bias score <0.5 indicates attention towards the other food images.
Measured before exercise/rest (t = -60 minutes) and after meal consumption (t= 30 minutes), morning and evening, exercise and rest
Secondary Reaction time (ms) Reaction time during forced food choice of food items from four combined food categories (high-fat savoury, high-fat sweet, low-fat savoury and low-fat sweet foods) examined from the computerized Leeds Food Preference Questionnaire. Measured before exercise/rest (t = -60 minutes) and after meal consumption (t= 30 minutes), morning and evening, exercise and rest
Secondary Explicit liking Explicit liking of 16 food items from four combined food categories (high-fat savoury, high-fat sweet, low-fat savoury and low-fat sweet foods) examined from the SBFPT. Explicit liking is rated using visual analogue scales and the range is 0-100. Each end represents the extremes e.g. Question: "how pleasant would it be to taste this food right now?" Answer: "not at all" (rated 0 on the 0-100 scale) to "extremely" (rated 100 on the 0-100 scale). Measured before exercise/rest (t = -60 minutes) and after meal consumption (t= 30 minutes), morning and evening, exercise and rest
Secondary Implicit wanting Implicit wanting of food items from four combined food categories (high-fat savoury, high-fat sweet, low-fat savoury and low-fat sweet foods) examined from the SBFPT. Implicit wanting is assessed based on food choice and response time for selected and non-selected food items as well as mean response time (a frequency-weighted algorithm).
In this frequency-weighted algorithm a positive score indicates a more rapid preference for a food type over another food type and a negative score indicates the opposite. A score of zero indicates that food types are equally preferred. The frequency weighted algorithm is used so the implicit wanting score is influenced by both selection (positively contributing to the score) and non-selection (negatively contributing to the score) of food type. Scores for implicit wanting typically range from -100-100 (due to reaction time there is no fixed min-max value)
Measured before exercise/rest (t = -60 minutes) and after meal consumption (t= 30 minutes), morning and evening, exercise and rest
Secondary Explicit wanting Explicit wanting of 16 food items from four combined food categories (high-fat savoury, high-fat sweet, low-fat savoury and low-fat sweet foods) examined from the SBFPT. Explicit wanting is rated using visual analogue scales and the range is 0-100. Each end represents the extremes e.g. Question: "how much do you want some of this food now?" Answer: "not at all" (rated 0 on the 0-100 scale) to "extremely" (rated 100 on the 0-100 scale). Measured before exercise/rest (t = -60 minutes) and after meal consumption (t= 30 minutes), morning and evening, exercise and rest
Secondary Subjective appetite Rated using visual analogue scales and includes sensations of: Hunger, fullness, satiety, prospective food consumption, wellbeing, nausea, thirst, desire to eat meat, salty, and sweet. The scale range is 0-100 and each end represent the extremes e.g. hunger rating: "I am not hungry at all" to "I have never been this hungry before". Fasting (t = -60, 0 minutes) and at t = 0, 15, 30, 45, 60 minutes, morning and evening, exercise and rest
Secondary Energy intake (KJ) Assessed from diet records Registered 24 hours after the test days, morning and evening, exercise and rest
Secondary Borg RPE Subjective rating of the level of exertion during exercise is collected through the Borg Rating of Percieved Exertion (RPE) at baseline and post exercise, and compared between visits. Measured after exercise (t = 0 minutes) , morning and evening
See also
  Status Clinical Trial Phase
Completed NCT05219994 - Targeting the Carotid Bodies to Reduce Disease Risk Along the Diabetes Continuum N/A
Completed NCT04056208 - Pistachios Blood Sugar Control, Heart and Gut Health Phase 2
Completed NCT02284893 - Study to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin in Combination With Metformin Compared to Sitagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone Phase 3
Completed NCT04274660 - Evaluation of Diabetes and WELLbeing Programme N/A
Active, not recruiting NCT05887817 - Effects of Finerenone on Vascular Stiffness and Cardiorenal Biomarkers in T2D and CKD (FIVE-STAR) Phase 4
Active, not recruiting NCT05566847 - Overcoming Therapeutic Inertia Among Adults Recently Diagnosed With Type 2 Diabetes N/A
Recruiting NCT06007404 - Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
Completed NCT04965506 - A Study of IBI362 in Chinese Patients With Type 2 Diabetes Phase 2
Recruiting NCT06115265 - Ketogenic Diet and Diabetes Demonstration Project N/A
Active, not recruiting NCT03982381 - SGLT2 Inhibitor or Metformin as Standard Treatment of Early Stage Type 2 Diabetes Phase 4
Completed NCT04971317 - The Influence of Simple, Low-Cost Chemistry Intervention Videos: A Randomized Trial of Children's Preferences for Sugar-Sweetened Beverages N/A
Completed NCT04496154 - Omega-3 to Reduce Diabetes Risk in Subjects With High Number of Particles That Carry "Bad Cholesterol" in the Blood N/A
Completed NCT04023539 - Effect of Cinnamomum Zeylanicum on Glycemic Levels of Adult Patients With Type 2 Diabetes N/A
Recruiting NCT05572814 - Transform: Teaching, Technology, and Teams N/A
Enrolling by invitation NCT05530356 - Renal Hemodynamics, Energetics and Insulin Resistance: A Follow-up Study
Completed NCT04097600 - A Research Study Comparing Active Drug in the Blood in Healthy Participants Following Dosing of the Current and a New Formulation (D) Semaglutide Tablets Phase 1
Completed NCT03960424 - Diabetes Management Program for Hispanic/Latino N/A
Completed NCT05378282 - Identification of Diabetic Nephropathy Biomarkers Through Transcriptomics
Recruiting NCT06010004 - A Long-term Safety Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes Phase 3
Completed NCT03653091 - Safety & Effectiveness of Duodenal Mucosal Resurfacing (DMR) Using the Revita™ System in Treatment of Type 2 Diabetes N/A